316 related articles for article (PubMed ID: 35403533)
1. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):333-339. PubMed ID: 35403533
[TBL] [Abstract][Full Text] [Related]
2. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Rizzo A; Ricci AD
Expert Opin Investig Drugs; 2022 Apr; 31(4):415-423. PubMed ID: 34429006
[TBL] [Abstract][Full Text] [Related]
3. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Rizzo A; Ricci AD; Di Federico A; Frega G; Palloni A; Tavolari S; Brandi G
Front Oncol; 2021; 11():803133. PubMed ID: 34976841
[TBL] [Abstract][Full Text] [Related]
4. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
Lin ZF; Qin LX; Chen JH
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
[TBL] [Abstract][Full Text] [Related]
6. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
Chan LL; Chan SL
Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
[TBL] [Abstract][Full Text] [Related]
7. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
8. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
9. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
Rizzo A; Ricci AD; Brandi G
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma.
Muhammed A; D'Alessio A; Enica A; Talbot T; Fulgenzi CAM; Nteliopoulos G; Goldin RD; Cortellini A; Pinato DJ
Expert Rev Mol Diagn; 2022 Mar; 22(3):253-264. PubMed ID: 35236211
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy.
Nikoo M; Hassan ZF; Mardasi M; Rostamnezhad E; Roozbahani F; Rahimi S; Mohammadi J
Pathol Res Pract; 2023 Jul; 247():154473. PubMed ID: 37207558
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond.
Rizzo A; Ricci AD
Expert Opin Investig Drugs; 2022 Jun; 31(6):549-555. PubMed ID: 34793275
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
14. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
Ji JH; Ha SY; Lee D; Sankar K; Koltsova EK; Abou-Alfa GK; Yang JD
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108802
[TBL] [Abstract][Full Text] [Related]
15. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
[TBL] [Abstract][Full Text] [Related]
16. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
Hewitt DB; Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
[No Abstract] [Full Text] [Related]
17. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
Guardascione M; Toffoli G
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
[TBL] [Abstract][Full Text] [Related]
18. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
19. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
Zhu Y; Qin LX
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
[TBL] [Abstract][Full Text] [Related]
20. Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.
Reiter FP; Ben Khaled N; Ye L; Zhang C; Seidensticker M; Op den Winkel M; Denk G; Geier A; De Toni EN
Dig Dis; 2022; 40(5):565-580. PubMed ID: 34644705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]